Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
1.930
+0.030 (1.58%)
At close: Apr 28, 2026, 4:00 PM EDT
1.960
+0.030 (1.55%)
After-hours: Apr 28, 2026, 6:23 PM EDT

Company Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company.

It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.

The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.

In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform.

Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics, Inc.
Bluejay Diagnostics logo
Country United States
Founded 2015
IPO Date Nov 10, 2021
Industry Medical Devices
Sector Healthcare
Employees 6
CEO Indranil Dey

Contact Details

Address:
360 Massachusetts Avenue, Suite 203
Acton, Massachusetts 01720
United States
Phone 844 327 7078
Website bluejaydx.com

Stock Details

Ticker Symbol BJDX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001704287
CUSIP Number 095633608
ISIN Number US0956336087
Employer ID 47-3552922
SIC Code 3841

Key Executives

Name Position
Indranil Dey Principal Financial, Accounting and Executive Officer, President, Chief Executive Officer and Director
Kevin Vance Chief Commercial Officer
Mark W. Feinberg M.D., Ph.D. Chief Medical Advisor
Dr. Mark W. Feinberg M.D. Chief Medical Advisor

Latest SEC Filings

Date Type Title
Apr 20, 2026 PRE 14A Other preliminary proxy statements
Apr 7, 2026 8-K Current Report
Mar 17, 2026 8-K Current Report
Mar 16, 2026 8-K Current Report
Mar 12, 2026 8-K Current Report
Mar 11, 2026 SCHEDULE 13D Filing
Mar 11, 2026 SCHEDULE 13D Filing
Mar 11, 2026 SCHEDULE 13D Filing
Mar 6, 2026 10-K Annual Report
Mar 6, 2026 8-K Current Report